Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Sci Immunol. 2024 Oct 11;9(100):eadp5216. doi: 10.1126/sciimmunol.adp5216.
Rhesus cytomegalovirus (RhCMV) vectors elicit major histocompatibility complex (MHC)-E-restricted CD8 T cells that stringently control simian immunodeficiency virus (SIV) in rhesus macaques. These responses require deletion of eight RhCMV chemokine-like open reading frames (ORFs) that are conserved in human cytomegalovirus (HCMV). To determine whether HCMV encodes additional, nonconserved inhibitors of unconventional T cell priming, we inserted 41 HCMV-specific ORFs into a chemokine-deficient strain (68-1 RhCMV). Monitoring of epitope recognition revealed that HCMV UL18 prevented unconventional T cell priming, resulting in MHC-Ia-targeted responses. UL18 is homologous to MHC-I but does not engage T cell receptors and, instead, binds with high affinity to inhibitory leukocyte immunoglobulin-like receptor-1 (LIR-1). UL18 lacking LIR-1 binding no longer interfered with MHC-E-restricted T cell stimulation by RhCMV-infected cells or the induction of unconventionally restricted T cells. Thus, LIR-1 binding needs to be deleted from UL18 of HCMV/HIV vaccines to allow for the induction of protective MHC-E-restricted T cells.
恒河猴巨细胞病毒(RhCMV)载体引发主要组织相容性复合体(MHC)-E 限制性 CD8 T 细胞,严格控制恒河猴中的猴免疫缺陷病毒(SIV)。这些反应需要删除在人巨细胞病毒(HCMV)中保守的八个 RhCMV 趋化因子样开放阅读框(ORF)。为了确定 HCMV 是否编码额外的非保守的非常规 T 细胞启动抑制剂,我们将 41 个 HCMV 特异性 ORF 插入一个趋化因子缺陷株(68-1 RhCMV)中。表位识别的监测表明,HCMV UL18 阻止了非常规 T 细胞的启动,导致 MHC-Ia 靶向反应。UL18 与 MHC-I 同源,但不与 T 细胞受体结合,而是与高亲和力结合抑制性白细胞免疫球蛋白样受体-1(LIR-1)。缺乏 LIR-1 结合的 UL18 不再干扰 RhCMV 感染细胞或诱导非常规限制的 T 细胞对 MHC-E 限制性 T 细胞的刺激。因此,需要从 HCMV/HIV 疫苗的 UL18 中删除 LIR-1 结合,以允许诱导保护性 MHC-E 限制性 T 细胞。